Research on treatments for bone and ocular diseases using dental pulp stem cells with Showa University and Gifu Pharmaceutical University
First written in FY2020-Q2. 4 of 8 entries say "Restated". Latest entry: FY2022-Q3.
No other company in this theme has enough history to compare yet.
- FY2022-Q3RestatedAnnual report
「Multiple academic institutions and companies have assessed SHED's potential to provide new treatments in areas such as bone and neurological diseases, and the Company is advancing research and development activities with each of them. Clear efficacy against the relevant diseases has been confirmed in preclinical studies for numerous pipelines, and the programmes are steadily progressing toward out-licensing.」
The Company has reconfirmed that efficacy has been confirmed in preclinical studies for multiple pipelines using SHED in areas including bone and neurological diseases, and that the programmes are progressing toward out-licensing. - FY2022-Q2RestatedAnnual report
「Multiple academic institutions and companies have assessed SHED's potential to provide new treatments in areas such as bone and neurological diseases, and the Company is advancing research and development activities with each of them. Clear efficacy against the relevant diseases has been confirmed in preclinical studies for numerous pipelines, and the programmes are steadily progressing toward out-licensing.」
The Company has reconfirmed that efficacy has been confirmed in preclinical studies for multiple pipelines using SHED in areas including bone and neurological diseases, and that the programmes are progressing toward out-licensing. - FY2022-Q1AdvancedAnnual report
「Among these, clear efficacy of SHED against diseases has been confirmed in preclinical studies for numerous pipelines, and we are steadily progressing toward out-licensing.」
Research using SHED across multiple disease areas has demonstrated clear efficacy in preclinical studies, and the programmes are making concrete progress toward out-licensing. - FY2021-Q2AdvancedAnnual report
「Also in August, we entered into a three-party joint research agreement with Hokkaido University and the 総合せき損センター for the development of a treatment for intractable fractures using dental pulp stem cells.」
In addition to research into bone and eye diseases using dental pulp stem cells, the Company expanded the target diseases and research partners to include research into difficult-to-heal fractures with Hokkaido University and the Comprehensive Spinal Cord Injury Center. - FY2021-Q1RestatedAnnual report
「For dental pulp stem cells, the Company has had multiple academic institutions and companies assess their potential to provide new treatments in areas such as bone and neurological diseases by determining their suitability for treating diseases. During the previous consolidated fiscal year, the Company entered into joint research agreements with Showa University for bone-related diseases, Gifu Pharmaceutical University for eye-related diseases, and the Tokyo Metropolitan Institute of Medical Science, Nagoya University Hospital and Tokyo Medical and Dental University for cerebral palsy, as well as with Oita University for peripheral nerve paralysis and Nagoya University for spinal cord injuries. It also entered into a joint research and development agreement with ORTHOREBIRTH Co., Ltd. to create a treatment for cleft lip and palate, and a joint commercialisation agreement with Mochida Pharmaceutical Co.,Ltd. for regenerative medicine products for rare and intractable gastrointestinal diseases, including intestinal neuronal dysplasia. Research and development activities are being advanced under each agreement.」
Joint research with universities and research institutions is continuing across multiple disease areas, including bone and eye diseases, cerebral palsy, peripheral nerve paralysis and spinal cord injuries, using dental pulp stem cells. - FY2020RestatedAnnual report
「Specifically, the Company is conducting joint research with Showa University on bone-related diseases, Gifu Pharmaceutical University on eye-related diseases, the Tokyo Metropolitan Institute of Medical Science, Nagoya University Hospital and Tokyo Medical and Dental University on cerebral palsy, Oita University on peripheral nerve paralysis, and Nagoya University on spinal cord injuries.」
Joint research with universities using dental pulp stem cells is continuing in areas including bone and eye diseases, and the research scope is being expanded to multiple diseases. - FY2020-Q3AdvancedAnnual report
「In November 2019, the Company entered into an industry-academia partnership agreement with Showa University to broaden the potential for commercialising regenerative medicine using dental pulp stem cells.」
The Company's university collaboration, including research into bone and eye diseases using dental pulp stem cells, advanced to the stage of expanding the commercialisation potential of regenerative medicine through an industry-academia partnership agreement with Showa University. - FY2020-Q2First statedAnnual report
「The Company has steadily advanced the business by entering into a joint research and development agreement with ORTHOREBIRTH Co., Ltd. in May 2019 to create a treatment for cleft lip and palate, and joint research agreements with Showa University and Gifu Pharmaceutical University in September of the same year to create treatments for bone and eye diseases, respectively.」
The Company entered into joint research agreements with Showa University and Gifu Pharmaceutical University to create treatments for bone and eye diseases, respectively, using Cell Technology's dental pulp stem cells.